Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
…, P Moss, R Malladi, CF Craddock - Blood, The Journal …, 2012 - ashpublications.org
Strategies that augment a GVL effect without increasing the risk of GVHD are required to
improve the outcome after allogeneic stem cell transplantation (SCT). Azacitidine (AZA) up-…
improve the outcome after allogeneic stem cell transplantation (SCT). Azacitidine (AZA) up-…
[HTML][HTML] Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial
Disease relapse is the major causes of treatment failure after allogeneic stem cell
transplantation (SCT) in patients with acute myeloid leukemia (AML). As well as demonstrating …
transplantation (SCT) in patients with acute myeloid leukemia (AML). As well as demonstrating …
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
…, A Khan, R Salim, C Craddock… - Blood, The Journal …, 2020 - ashpublications.org
Relapse remains the most common cause of treatment failure for patients with acute myeloid
leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a …
leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a …
GWAS meta-analysis of suicide attempt: identification of 12 genome-wide significant loci and implication of genetic risks for specific health factors
…, B Chaumette, A Corvin, N Craddock… - American journal of …, 2023 - Am Psychiatric Assoc
Objective: Suicidal behavior is heritable and is a major cause of death worldwide. Two large-scale
genome-wide association studies (GWASs) recently discovered and cross-validated …
genome-wide association studies (GWASs) recently discovered and cross-validated …
Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature
CF Craddock, AE Houlton, LS Quek, P Ferguson… - Clinical Cancer …, 2017 - AACR
Purpose: Azacitidine (AZA) is a novel therapeutic option in older patients with acute myeloid
leukemia (AML), but its rational utilization is compromised by the fact that neither the …
leukemia (AML), but its rational utilization is compromised by the fact that neither the …
EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and …
…, BE Shaw, JL Byrne, C Brookes, CF Craddock… - Bone marrow …, 2014 - nature.com
EBV-associated post-transplant lymphoproliferative disease (PTLD) following Alemtuzumab-based
allo-SCT is a relatively uncommon and challenging clinical problem but has not …
allo-SCT is a relatively uncommon and challenging clinical problem but has not …
[HTML][HTML] An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell …
Up to 30% of adults with acute myeloid leukemia fail to achieve a complete remission after
induction chemotherapy-termed primary refractory acute myeloid leukemia. There is no …
induction chemotherapy-termed primary refractory acute myeloid leukemia. There is no …
[HTML][HTML] Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid …
C Craddock, D Slade, C De Santo… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE Salvage options for patients who relapse after allogeneic stem-cell transplantation
(allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, …
(allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, …
[HTML][HTML] FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Patients with FLT3-mutated AML have a high relapse rate and suboptimal outcomes. Many
have co-mutations suitable for measurable residual disease (MRD) monitoring by RT-qPCR …
have co-mutations suitable for measurable residual disease (MRD) monitoring by RT-qPCR …
[HTML][HTML] Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid …
Reduced intensity conditioning (RIC) transplantation is increasingly offered to older patients
with acute myeloblastic leukemia. We have previously shown that a RIC allograft, …
with acute myeloblastic leukemia. We have previously shown that a RIC allograft, …